NTLA Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -687.61% compared to Intellia Therapeutics's net margin of --. Intellia Therapeutics's return on equity of -56.9% beat Perspective Therapeutics's return on equity of --.

Intellia Therapeutics has a consensus price target of $40.56, signalling upside risk potential of 399.45%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.3929 which suggests that it could grow by 512.46%. Given that Perspective Therapeutics has higher upside potential than Intellia Therapeutics, analysts believe Perspective Therapeutics is more attractive than Intellia Therapeutics.

Intellia Therapeutics has a beta of 2.332, which suggesting that the stock is 133.227% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Intellia Therapeutics quarterly revenues are $16.6M, which are larger than Perspective Therapeutics quarterly revenues of --. Intellia Therapeutics's net income of -$114.3M is lower than Perspective Therapeutics's net income of -$40.2M. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 17.97x versus 15.21x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -687.61% compared to Intellia Therapeutics's net margin of 32.71%. Intellia Therapeutics's return on equity of -56.9% beat Merck &'s return on equity of 39.02%.

Intellia Therapeutics has a consensus price target of $40.56, signalling upside risk potential of 399.45%. On the other hand Merck & has an analysts' consensus of $105.02 which suggests that it could grow by 38.24%. Given that Intellia Therapeutics has higher upside potential than Merck &, analysts believe Intellia Therapeutics is more attractive than Merck &.

Intellia Therapeutics has a beta of 2.332, which suggesting that the stock is 133.227% more volatile than S&P 500. In comparison Merck & has a beta of 0.429, suggesting its less volatile than the S&P 500 by 57.139%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.16% to investors and pays a quarterly dividend of $0.81 per share. Intellia Therapeutics pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intellia Therapeutics quarterly revenues are $16.6M, which are smaller than Merck & quarterly revenues of $15.5B. Intellia Therapeutics's net income of -$114.3M is lower than Merck &'s net income of $5.1B. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while Merck &'s PE ratio is 11.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 17.97x versus 3.02x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -687.61% compared to Intellia Therapeutics's net margin of 26.7%. Intellia Therapeutics's return on equity of -56.9% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Intellia Therapeutics has a consensus price target of $40.56, signalling upside risk potential of 399.45%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $796.67 which suggests that it could grow by 51.6%. Given that Intellia Therapeutics has higher upside potential than Regeneron Pharmaceuticals, analysts believe Intellia Therapeutics is more attractive than Regeneron Pharmaceuticals.

Intellia Therapeutics has a beta of 2.332, which suggesting that the stock is 133.227% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.17% to investors and pays a quarterly dividend of $0.88 per share. Intellia Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Intellia Therapeutics quarterly revenues are $16.6M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Intellia Therapeutics's net income of -$114.3M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 17.97x versus 4.28x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

TransMedics Group has a net margin of -687.61% compared to Intellia Therapeutics's net margin of 17.89%. Intellia Therapeutics's return on equity of -56.9% beat TransMedics Group's return on equity of 23.22%.

Intellia Therapeutics has a consensus price target of $40.56, signalling upside risk potential of 399.45%. On the other hand TransMedics Group has an analysts' consensus of $121.14 which suggests that it could grow by 8.65%. Given that Intellia Therapeutics has higher upside potential than TransMedics Group, analysts believe Intellia Therapeutics is more attractive than TransMedics Group.

Intellia Therapeutics has a beta of 2.332, which suggesting that the stock is 133.227% more volatile than S&P 500. In comparison TransMedics Group has a beta of 1.906, suggesting its more volatile than the S&P 500 by 90.573%.

Intellia Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics pays -- of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend.

Intellia Therapeutics quarterly revenues are $16.6M, which are smaller than TransMedics Group quarterly revenues of $143.5M. Intellia Therapeutics's net income of -$114.3M is lower than TransMedics Group's net income of $25.7M. Notably, Intellia Therapeutics's price-to-earnings ratio is -- while TransMedics Group's PE ratio is 81.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics is 17.97x versus 8.34x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.